Method for Production of Radioisotope Preparations and Theiruse in Life Science, Research, Medical Application and Industry

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a universal, scalable method for producing high-purity, carrier-free or non-carrier-added radioisotopes. The method uses a series of advanced, modular processes (unit operations) derived from physics and materials science, many of which are not traditionally used in isotope production. It allows for both batch and continuous (fully automated) production. The produced radioisotopes are especially suitable for labeling bioconjugates, nanoparticles, and microparticles, which are crucial in modern medical diagnostics, therapies (such as cancer treatment via radioimmunotherapy and targeted alpha therapy), research, and industrial applications.

Use CasesContent extracted from patent full text and abstract with AI.

• Large-scale production of high-purity radioisotopes for nuclear medicine, notably for diagnostic imaging (PET, SPECT) and targeted therapies (radioimmunotherapy, targeted alpha therapy, Auger-therapy) in cancer treatment.
• Manufacturing of radioisotope-labeled bioconjugates, such as antibodies and peptides, for highly specific disease diagnosis and therapy.
• Production of radioisotope-labeled nanoparticles, microparticles, and microspheres for use in selective internal radiation therapy (SIRT) and radioembolization treatments.
• Generation of specialized isotope generators (e.g., 225Ac/213Bi, 62Zn/62Cu, 44Ti/44Sc, 228Th/224Ra) to supply hospitals and research centers with short-lived isotopes.
• Supplying isotopes for research in life sciences, pharmacokinetics, dosimetry, and in vitro/in vivo tracing studies.
• Recovery and recycling of valuable radioisotopes from nuclear accelerator waste streams and other by-products, minimizing radioactive waste.
• Direct labelling of chromatographic media and matrices used in chemical and biochemical analysis with specific radioisotopes.
• Production of neutron-rich lanthanide and tin isotopes for emerging therapeutic and industrial applications.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables production of carrier-free or non-carrier-added isotopes with extremely high specific activity and purity, essential for sensitive medical and research applications.
• Highly versatile and modular process, adaptable for a wide range of isotopes and target materials—can be customized for specific application requirements or isotope characteristics.
• Suitable for both batch and fully automated continuous operation, allowing for industrial-scale, reliable, and efficient production.
• Significantly expands the range and availability of medically and industrially important radioisotopes, including rare and previously inaccessible isotopes.
• Minimizes waste—method operates with dry separation techniques, generating primarily solid waste and little to no liquid radioactive waste, addressing both environmental and safety concerns.
• Facilitates direct labeling of bioconjugates, nanoparticles, and other platforms, often yielding stronger, more stable bonds than chemical labeling methods.
• Improves safety and efficiency by enabling non-destructive processing and the re-use of target materials, reducing costs and resource consumption.
• Supports the development of new diagnostics and therapies, such as next-generation cancer treatments, by providing isotopes with optimal decay and emission properties.
• Allows harvesting of valuable isotopes from existing accelerator waste streams, turning a disposal challenge into a resource.
• Can produce customized or mono-isotopic radionuclide preparations, enabling tailored solutions for advanced imaging, personalized medicine, and emerging therapy techniques.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to an universal method for the large scale production of high-purity carrier free or non carrier added radioisotopes by applying a number of "unit operations" which are derived from physics and material science and hitherto not used for isotope production. A required number of said unit operations is combined, selected and optimised individually for each radioisotope production scheme. The use of said unit operations allows a batch wise operation or a fully automated continuous production scheme. The radioisotopes produced by the inventive method are especially suitable for producing radioisotope-labelled bioconjugates as well as particles, in particular nanoparticles and microparticles.